Survodutide vs AICAR
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideAnti-Aging & LongevityFat Loss & Metabolic
AICAR- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
- Half-Life
- ~7 days
- ~2–3 hours
- Admin Route
- SubQ
- SubQ, IV
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 25–50 mg
- Frequency
- Once weekly
- 3–5 times per week
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- AMPK activation mimics aerobic exercise adaptations
- Increased fat oxidation and endurance
- Mitochondrial biogenesis (PGC-1alpha)
- Improved insulin sensitivity and glucose metabolism
- Anti-inflammatory effects
- Potential cardiac protection during ischemia
- Synergistic with actual exercise training
- Reduces hepatic glucose production
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Hypoglycemia risk
- Lactic acidosis at high doses (animal data)
- Injection site irritation
- Stacks With
- —
- —